The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example.
Arthritis, Psoriatic
/ diagnostic imaging
Arthritis, Rheumatoid
/ diagnostic imaging
Consensus
Enthesopathy
/ diagnostic imaging
Humans
Musculoskeletal System
/ diagnostic imaging
Outcome Assessment, Health Care
/ methods
Research Design
Rheumatology
/ methods
Severity of Illness Index
Synovitis
/ diagnostic imaging
Tenosynovitis
/ diagnostic imaging
Ultrasonography
OFISA
OMERACT
OUTCOME MEASUREMENT INSTRUMENT
ULTRASOUND
VALIDATION
Journal
The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
accepted:
31
01
2019
pubmed:
17
3
2019
medline:
20
11
2020
entrez:
17
3
2019
Statut:
ppublish
Résumé
To describe the Outcome Measures in Rheumatology (OMERACT) stepwise approach to select and develop an imaging instrument with musculoskeletal ultrasound (US) as an example. The OMERACT US Working Group (WG) developed a 4-step process to select instruments based on imaging. Step 1 applies the OMERACT Framework Instrument Selection Algorithm (OFISA) to existing US outcome measurement instruments for a specific indication. This step requires a literature review focused on the truth, discrimination, and feasibility aspects of the instrument for the target pathology. When the evidence is completely unsatisfactory, Step 2 is a consensus process to define the US characteristics of the target pathology including one or more so-called "elementary lesions". Step 3 applies the agreed definitions to the image, evaluates their reliability, develops a severity grading of the lesion(s) at a given anatomical site, and evaluates the effect of the acquisition technique on feasibility and lesion(s) detection. Step 4 applies and assesses the definition(s) and scoring system(s) in cross-sectional studies and multicenter trials. The imaging instrument is now ready to pass a final OFISA check. With this process in place, the US WG now has 18 subgroups developing US instruments in 10 different diseases. Half of them have passed Step 3, and the groups for enthesitis (spondyloarthritis, psoriatic arthritis), synovitis, and tenosynovitis (rheumatoid arthritis) have finished Step 4. The US WG approach to select and develop outcome measurement instruments based on imaging has been repeatedly and successfully applied in US, but is generic for imaging and fits with OMERACT Filter 2.1.
Identifiants
pubmed: 30877208
pii: jrheum.181158
doi: 10.3899/jrheum.181158
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1394-1400Subventions
Organisme : Department of Health
Pays : United Kingdom